A Study Of Indian Patients Receiving Therapy For Systemic Fungal Infections

Pfizer

Status: Completed

Conditions: Systemic Fungal Infections

Treatments: Drug: voriconazole

Study type: Observational

Funder types: Industry

Identifiers

NCT00721578

A1501089

Details and patient eligibility

About

To collect and summarize information on the diagnosis, management, and clinical and mycological outcomes of patients with systemic fungal infections in order to better understand the effectiveness of antifungals in the treatment of Systemic Fungal Infections (SFI) in India.

Enrollment: 23 patients

Sex: All

Ages: 18 to 75 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• To be eligible for enrollment in the study database, patients must have received (in the Intensive Care Unit [ICU] at study entry) at least 1 day therapy with systemic antifungal agent for treatment of a proven or suspected fungal infection.

Exclusion criteria

• None.

Trial design

23 participants in 1 patient group

1

Treatment:

Drug: voriconazole